About the Authors
- Ana de la Cueva
-
Current address: IMDEA Food Institute, Madrid, Spain
Affiliation Traslational Oncology Unit, Instituto de Investigaciones Biomédicas, CSIC, Madrid, Spain
- Ana Ramírez de Molina
-
Current address: IMDEA Food Institute, Madrid, Spain
Affiliation Traslational Oncology Unit, Instituto de Investigaciones Biomédicas, CSIC, Madrid, Spain
- Néstor Álvarez-Ayerza
-
Affiliation Traslational Oncology Unit, Instituto de Investigaciones Biomédicas, CSIC, Madrid, Spain
- Ma Angeles Ramos
-
Affiliation Traslational Oncology Unit, Instituto de Investigaciones Biomédicas, CSIC, Madrid, Spain
- Arancha Cebrián
-
Current address: Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
Affiliation Traslational Oncology Unit, Instituto de Investigaciones Biomédicas, CSIC, Madrid, Spain
- Teresa Gómez del Pulgar
-
Current address: Centro Nacional de Investigaciones Oncológicas, Madrid, Spain
Affiliation Traslational Oncology Unit, Instituto de Investigaciones Biomédicas, CSIC, Madrid, Spain
- Juan Carlos Lacal
-
* E-mail: jclacal@iib.uam.es
Affiliations Traslational Oncology Unit, Instituto de Investigaciones Biomédicas, CSIC, Madrid, Spain, Instituto de Investigación Sanitaria IdiPAZ, Madrid, Spain
Competing Interests
Juan Carlos Lacal is a founder of TCD Pharma and a member of its scientific advisory board but not an employee of the company. TCD Pharma is developing the compound TCD717, a ChoKα inhibitor, that is currently in Phase I clinical trials. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: ARDM JCL TGDP AC. Performed the experiments: ADLC ARDM NAA MAR. Analyzed the data: ADLC ARDM JCL TGDP AC. Wrote the paper: ADLC ARDM TGDP AC JCL.